Advice Regarding Systemic Therapy in Patients with Urological Cancers During the COVID-19 Pandemic.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 32312544.
- Also identified by DOI 10.1016/j.eururo.2020.03.026 and PMC identifier 7164868.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The risk/benefit ratio of a number of palliative and (neo)adjuvant treatments should be reconsidered during the COVID-19 pandemic. We provide treatment advice as a pragmatic perspective on the risk/benefit ratio in specific clinical scenarios.
Medical subject headings
- Antineoplastic Combined Chemotherapy Protocols
- Betacoronavirus
- Coronavirus Infections
- Disease Transmission, Infectious
- Pneumonia, Viral
- Urologic Neoplasms